Latest News

Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC
Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC

June 21st 2025

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Savolitinib Plus Osimertinib Elicits Durable Responses in MET+ Advanced NSCLC
Savolitinib Plus Osimertinib Elicits Durable Responses in MET+ Advanced NSCLC

June 20th 2025

Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC

June 19th 2025

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

June 19th 2025

Dato-DXd Combination Is Effective in Post-TKI NSCLC
Dato-DXd Combination Is Effective in Post-TKI NSCLC

June 19th 2025

Video Series
Video Interviews
Podcasts

More News